Evidence map›Paper›PMID 16434970›Full record

ArticleOncogene2006

Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt.

Y-H Han, X Cao, B Lin, F Lin, S K Kolluri, J Stebbins, J C Reed, M I Dawson, X-K Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 143 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Ethyl Acetate Fraction ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Y-H HanBurnham Institute for Medical Research, Cancer Center, La Jolla, CA 92037, USA.
X Cao
B Lin
F Lin
S K Kolluri
J Stebbins
J C Reed
M I Dawson
X-K Zhang
Sanford Burnham Prebys Medical Discovery Institute · US

Funding

15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalphaR01CA109345 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ZHANG, XIAO-KUN · 2004 to 2009
$2.4M
TR3/nur77 in Survival and Death of Cancer CellsR01CA087000 · NCI · BURNHAM INSTITUTE FOR MEDICAL RESEARCH · PI ZHANG, XIAO-KUN · 2001 to 2005
$1.5M
NCI NIH HHS CA109345NCI NIH HHS CA87000NIGMS NIH HHS GM60544
6 · The paper itself

Abstract

Proapoptotic nuclear receptor family member Nur77 translocates from the nucleus to the mitochondria, where it interacts with Bcl-2 to trigger apoptosis. Nur77 translocation is induced by certain apoptotic stimuli, including the synthetic retinoid-related 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN)/CD437 class. In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces Nur77 nuclear export. Our results demonstrate that 3-Cl-AHPC effectively activated Jun N-terminal kinase (JNK), which phosphorylates Nur77. Inhibition of JNK activation by a JNK inhibitor suppressed 3-Cl-AHPC-induced Nur77 nuclear export and apoptosis. In addition, several JNK upstream activators, including the phorbol ester TPA, anisomycin and MAPK kinase kinase-1 (MEKK1), phosphorylated Nur77 and induced its nuclear export. However, Nur77 phosphorylation by JNK, although essential, was not sufficient for inducing Nur77 nuclear export. Induction of Nur77 nuclear export by MEKK1 required a prolonged MEKK1 activation and was attenuated by Akt activation. Expression of constitutively active Akt prevented MEKK1-induced Nur77 nuclear export. Conversely, transfection of dominant-negative Akt or treatment with a phosphatidylinositol 3-kinase (PI3-K) inhibitor accelerated MEKK1-induced Nur77 nuclear export. Furthermore, mutation of an Akt phosphorylation residue Ser351 in Nur77 abolished the effect of Akt or the PI3-K inhibitor. Together, our results demonstrate that both activation of JNK and inhibition of Akt play a role in translocation of Nur77 from the nucleus to the cytoplasm.

Indexed as

Protein Processing, Post-TranslationalAdamantaneAnisomycinApoptosisCell Line, TumorCell NucleusCinnamatesDNA-Binding ProteinsEnzyme ActivationFlavonoidsHumansImidazolesJNK Mitogen-Activated Protein KinasesMAP Kinase Kinase 7MAP Kinase Kinase Kinase 1Mutagenesis, Site-Directed2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acidAdamantaneAKT1 protein, humanAnisomycinCinnamatesDNA-Binding ProteinsFlavonoidsImidazolesJNK Mitogen-Activated Protein KinasesMAP2K7 protein, humanMAP3K1 protein, humanMAP Kinase Kinase 7MAP Kinase Kinase Kinase 1NR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2PyridinesReceptors, Cytoplasmic and NuclearReceptors, SteroidRecombinant Fusion ProteinsSB 203580Tetradecanoylphorbol AcetateTranscription Factors

Identifiers

PMID16434970
OpenAlexW2033161660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.